Like you know something isn’t right with your health, but the doctor either dismissed your concerns or prescribed a ...

Atopic dermatitis, a chronic skin condition, is common in children and requires treatment to minimise frequent flares. Dr Ker ...

Pfizer says the drugs seem to have an impact on itch – often cited as the most bothersome symptom in atopic dermatitis. Aurion Biotech has launched its cell therapy Vyznova for serious eye ...

Skin lesions commonly affect the paws (between the toes), face (around the lips/muzzle and eyes), ears, hairless regions (belly, armpits, groin), and legs (commonly on the front legs in front of the ...

Under the terms of the deal—which is expected to close ... With Vtama's success in relieving itching, Dermavant eyes FDA ...

Often thought of as simple redness of the skin, eczema is a chronic inflammatory skin condition that most often results in ...

Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...

Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic ...

It is not known if DUPIXENT is safe and effective in children with atopic dermatitis under 6 months of age ... including if you: have eye problems. have a parasitic (helminth) infection.

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...

As Eli Lilly and Co. launches its recently approved Ebglyss (lebrikizumab) in an atopic dermatitis market already dominated by established biologic Dupixent (dupilumab, Regeneron Pharmaceuticals Inc.) ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...